Medifast Dirección

Dirección controles de criterios 3/4

El CEO de Medifast es Dan Chard , nombrado en Oct 2016, tiene una permanencia de 8.08 años. compensación anual total es $7.04M, compuesta por 14.2% salario y 85.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.46% de las acciones de la empresa, por valor de $2.87M. La antigüedad media del equipo directivo y de la junta directiva es de 4.7 años y 8.1 años, respectivamente.

Información clave

Dan Chard

Chief Executive Officer (CEO)

US$7.0m

Compensación total

Porcentaje del salario del CEO	14.2%
Permanencia del CEO	8.1yrs
Participación del CEO	1.5%
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Chard en comparación con los beneficios de Medifast?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$7m
Jun 30 2024	n/a	n/a	US$29m
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$7m	US$1m	US$99m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$133m
Mar 31 2023	n/a	n/a	US$142m
Dec 31 2022	US$6m	US$981k	US$144m
Sep 30 2022	n/a	n/a	US$151m
Jun 30 2022	n/a	n/a	US$157m
Mar 31 2022	n/a	n/a	US$165m
Dec 31 2021	US$7m	US$914k	US$164m
Sep 30 2021	n/a	n/a	US$158m
Jun 30 2021	n/a	n/a	US$150m
Mar 31 2021	n/a	n/a	US$125m
Dec 31 2020	US$6m	US$909k	US$103m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$76m
Mar 31 2020	n/a	n/a	US$76m
Dec 31 2019	US$5m	US$843k	US$78m
Sep 30 2019	n/a	n/a	US$74m
Jun 30 2019	n/a	n/a	US$72m
Mar 31 2019	n/a	n/a	US$64m
Dec 31 2018	US$2m	US$675k	US$56m
Sep 30 2018	n/a	n/a	US$47m
Jun 30 2018	n/a	n/a	US$40m
Mar 31 2018	n/a	n/a	US$34m
Dec 31 2017	US$2m	US$650k	US$28m

Compensación vs. Mercado: La compensación total de Dan($USD7.04M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD736.76K).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Chard (59 yo)

8.1yrs

Permanencia

US$7,039,062

Compensación

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Chard	Executive Chairman & CEO	8.1yrs	US$7.04m	1.46% $ 2.9m
James Maloney	Chief Financial Officer	4.3yrs	US$2.01m	0.092% $ 179.5k
Anthony Tyree	Chief Business Operations Officer	2.8yrs	US$1.61m	0.12% $ 229.6k
Jason Groves	Executive VP	13yrs	US$1.63m	0.12% $ 228.6k
Nicholas Johnson	Chief Field Operations Officer	5.8yrs	US$1.70m	0.095% $ 186.9k
Jonathan MacKenzie	VP of Finance & Chief Accounting Officer	3.2yrs	sin datos	0.0052% $ 10.2k
Steven Zenker	Vice President of Investor Relations	1.7yrs	sin datos	sin datos
Claudia Greninger	Chief Human Resources Officer	5.1yrs	sin datos	sin datos

4.7yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0K05 se considera experimentado (4.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Chard	Executive Chairman & CEO	8.1yrs	US$7.04m	1.46% $ 2.9m
Jeffrey Brown	Lead Independent Director	9.4yrs	US$263.42k	0.15% $ 287.1k
George Bray	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michael Hoer	Independent Director	6.4yrs	US$249.72k	0.079% $ 154.2k
Andrea Thomas	Independent Director	5.4yrs	US$249.72k	0.059% $ 115.1k
John Foreyt	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ming Xian	Independent Director	6.4yrs	US$219.61k	sin datos
Lawrence Cheskin	Chairman of Scientific Advisory Board	16yrs	sin datos	sin datos
Sylvia Rowe	Member of Scientific Advisory Board	no data	sin datos	sin datos
Scott Schlackman	Independent Director	9.4yrs	US$252.44k	0.073% $ 143.3k
John Hayes	Member of Scientific Advisory Board	no data	sin datos	sin datos
Mark Messina	Member of Scientific Advisory Board	no data	sin datos	sin datos

8.1yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0K05 se considera experimentada (8.1 años de antigüedad promedio).

Medifast Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently sold US$109k worth of stock

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Insufficient new directors

Lead Independent Director recently bought US$499k worth of stock

Medifast Announces New Scientific Advisory Board Appointments

Executive Chairman & CEO recently bought US$79k worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023)

Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$2.78 profit in 2Q 2023)

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Now 43% overvalued

Now 46% overvalued

Now 52% overvalued

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 24%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023)

Now 22% overvalued

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Investor sentiment deteriorates as stock falls 16%

Independent Director recently sold US$109k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022)

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Now 20% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022)

Medifast Unveils New Product Line, Optavia Active

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast, Inc., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released: EPS: US$3.68 (vs US$3.62 in 1Q 2022)

Now 26% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$12.82 (vs US$14.01 in FY 2021)

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$3.30 (vs US$3.59 in 3Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Year 2022

Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of US$1.64 per share

Medifast Announces Quarterly Dividend, Payable on November 8, 2022

Now 20% undervalued after recent price drop

Lead Independent Director recently bought US$499k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021)

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast Announces New Scientific Advisory Board Appointments

Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index

Upcoming dividend of US$1.64 per share

Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022

Executive Chairman & CEO recently bought US$79k worth of stock

First quarter 2022 earnings released

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Insufficient new directors

Medifast, Inc., Annual General Meeting, Jun 15, 2022

Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022